Poor
Not Aligned
Patient Risk:
Moderate
Summary
The AI response includes mostly non-label claims (mechanistic/efficacy language and patent/market expectations) that are not supported by the provided FDA label excerpts. Even when some statements align generally with label text (e.g., binding to CD20 is described), several safety-relevant items, dosing/administration, contraindications, and warnings are not addressed, indicating substantial mismatch with the supplied prescribing information.
Category Scores
Accurate Statements
Ocrevus is also known as ocrelizumab.
Label excerpts identify the product as OCREVUS (ocrelizumab), supporting that ocrelizumab is the active ingredient name associated with OCREVUS (Section 1 and provided context).
Ocrevus targets CD20.
Label (12 CLINICAL PHARMACOLOGY) states therapeutic effects are presumed to involve binding to CD20.
CD20 is a protein found on the surface of B cells.
Label (12 CLINICAL PHARMACOLOGY) describes CD20 as a cell surface antigen present on pre-B and mature B lymphocytes.
Ocrevus is a humanized monoclonal antibody.
Not supported by the provided excerpts.
Unsupported Statements
Ocrevus is a humanized monoclonal antibody.
No provided label excerpt describes OCREVUS as humanized.
By selectively targeting and eliminating B cells, Ocrevus reduces the production of inflammatory cytokines.
The provided excerpts do not state elimination of B cells or reduction of inflammatory cytokines as a mechanism.
Ocrevus slows the progression of multiple sclerosis.
Label excerpts provided do not explicitly state 'slows the progression' (they include indications and trial efficacy references without this exact phrasing).
Ocrevus has been shown to significantly improve patient outcomes.
No provided label excerpt uses this statement; efficacy excerpts are limited to 'efficacy was demonstrated' without 'significantly improve patient outcomes' wording.
Ocrevus reduces relapse rates in multiple sclerosis.
No provided label excerpt explicitly states reduction in relapse rates.
Ocrevus slows disability progression.
No provided label excerpt explicitly states slowing disability progression.
Ocrevus is protected by multiple patents worldwide.
The provided FDA label excerpts do not include patent or regulatory exclusivity information.
US Patent 8,680,755 titled "Humanized monoclonal antibodies against CD20" was granted to Hoffmann-La Roche in 2014.
Not included in the provided FDA label excerpts.
US Patent 8,680,755 covers the composition of matter for ocrelizumab.
Not included in the provided FDA label excerpts.
US Patent 8,680,755 covers the use of ocrelizumab in treating autoimmune diseases, including multiple sclerosis.
Not included in the provided FDA label excerpts.
US Patent 9,264,444 titled "Methods for treating autoimmune diseases using ocrelizumab" was granted to Hoffmann-La Roche in 2016.
Not included in the provided FDA label excerpts.
US Patent 9,264,444 covers methods for treating autoimmune diseases, including multiple sclerosis, using ocrelizumab.
Not included in the provided FDA label excerpts.
EP Patent 2,342,444 titled "Humanized monoclonal antibodies against CD20" was granted to Hoffmann-La Roche in 2014.
Not included in the provided FDA label excerpts.
EP Patent 2,342,444 covers the composition of matter for ocrelizumab.
Not included in the provided FDA label excerpts.
EP Patent 2,342,444 covers the use of ocrelizumab in treating autoimmune diseases, including multiple sclerosis.
Not included in the provided FDA label excerpts.
The US patent for Ocrevus is set to expire in 2029.
Not included in the provided FDA label excerpts.
The European patent for Ocrevus is set to expire in 2031.
Not included in the provided FDA label excerpts.
As patents expire, generic versions of Ocrevus are expected to enter the market.
Not included in the provided FDA label excerpts.
The entry of generic versions of Ocrevus is expected to drive down costs.
Not included in the provided FDA label excerpts.
The entry of generic versions of Ocrevus is expected to increase patient access.
Not included in the provided FDA label excerpts.
Ocrevus is protected by composition of matter patents and method patents.
Not included in the provided FDA label excerpts.
Contradictions
Important Omissions
The AI response provides no FDA-label-aligned dosing/administration instructions (initial split dose two weeks apart; subsequent every 6 months; pediatric dosing by body weight; infusion observation and at least 1 hour post-infusion monitoring).
Importance:
High
The AI response provides no FDA-label contraindications (active HBV infection; history of life-threatening infusion reaction).
Importance:
High
The AI response provides no FDA-label safety/monitoring precautions (infection assessment and delay in active infection; HBV screening and consultation for HBcAb+ or carriers; infusion reaction monitoring; live vaccine timing; quantitative serum immunoglobulin monitoring; PML withholding/discontinue guidance; liver injury monitoring; immune-mediated colitis monitoring).
Importance:
High
Safety Assessment
Potential Patient Risk:
Moderate
No direct contradictions were identified, but the response largely omits critical FDA label safety elements (contraindications, infection/HBV/vaccine guidance, infusion reaction monitoring, and other precautions), which could lead to unsafe application if treated as prescribing guidance.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most claims are absent from the provided FDA label excerpts, especially those about patent coverage/expiration and market expectations; additional mechanistic and efficacy phrasing is not supported by the provided label text.
Suggested Improvement
Limit claims to what the provided label excerpts support (e.g., CD20 binding; labeled indications; required administration and monitoring elements) and exclude patent/expiration and generic-market predictions unless sourced from the FDA label.